nadolol and bendroflumethiazide

Action and Spectrum

Actions and spectrum:

nadolol and bendroflumethiazide are both medications used to treat hypertension, but they work in different ways. nadolol is a beta-blocker that acts by blocking the adrenaline effects on the heart and blood vessels, leading to a decrease in heart rate and blood pressure. This medication is also used to treat angina and heart failure.

Bendroflumethiazide is a thiazide diuretic that works by increasing the amount of salt and water excreted in the urine, which reduces the volume of blood and decreases blood pressure. Thiazide diuretics are often used as a first-line treatment for hypertension.

The combination of nadolol and bendroflumethiazide is used to treat hypertension in patients who require both a beta-blocker and a diuretic. By using two medications with different mechanisms of action, blood pressure can be lowered more effectively than with either medication alone.

Drug Interaction

Adverse Reaction

Frequency undefined: 

nadolol

• Abdominal discomfort
• Diarrhea
• Nausea
• Nasal congestion
• Insomnia
• Decreased sexual ability
• Dizziness
• Hypotension
• Constipation
• CHF
• Cough
• Drowsiness
• Palpitation
• Bradycardia
• Fatigue 

bendroflumethiazide

• Hypotension
• Phototoxicity
• Hyperuricemia
• Hypercholesterolemia
• Hypokalemia
• Hyponatremia
• Anorexia
• Hypercalcemia
• Hyperlipidemia
• Hypochloremia
• Hypomagnesemia
• Glucose intolerance

Black Box Warning

Black Box Warning

nadolol has a black box warning for abrupt cessation of therapy in patients with angina and for patients with coronary artery disease who are undergoing major surgery. It is important to taper the dose gradually over 1-2 weeks to avoid exacerbation of angina or myocardial infarction.

Contraindication / Caution

Contraindication/Caution

Contraindication

• Hypersensitivity to nadolol or bendroflumethiazide or to any ingredient in the formulation
• Sinus bradycardia, cardiogenic shock, or overt cardiac failure
• Anuria or significant renal impairment (creatinine clearance less than 30 mL/min)
• Severe hepatic impairment
• History of bronchial asthma, bronchospasm, or related bronchial disorders 

Caution

• Patients with allergic reactions or asthma should use nadolol and Bendroflumethiazide with caution, as the medication may cause bronchospasm.
• Patients with a history of diabetes or hypoglycemia should use nadolol and Bendroflumethiazide with caution, as the medication may mask some of the signs of low blood sugar.
• Patients with liver disease should use nadolol and Bendroflumethiazide with caution, as the medication may cause hepatic encephalopathy.
• Patients with kidney disease should use nadolol and Bendroflumethiazide with caution, as the medication may worsen renal function.
• Patients with a history of depression should use nadolol and Bendroflumethiazide with caution, as the medication may worsen depression symptoms.
• Patients with a history of gout should use nadolol and Bendroflumethiazide with caution, as the medication may increase the risk of gout attacks. 

Comorbidities

• Bradycardia
• Heart block greater than first degree
• Decompensated heart failure
• Cardiogenic shock
• Sick sinus syndrome
• Asthma
• COPD
• Renal impairment
• Hepatic impairment
• Hyperlipidemia
• Diabetes
• Gout
• Psoriasis
• Thyroid dysfunction
• Pheochromocytoma
• Hypoglycemia
• Peripheral vascular disease

Pregnancy / Lactation

Pregnancy consideration: pregnancy category C

Lactation: use caution as it is excreted in breast milk 

Pregnancy category:

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
• Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
• Category N: There is no data available for the drug under this category.

Pharmacology

Pharmacology

nadolol and bendroflumethiazide are combination medications used to treat hypertension (high blood pressure). nadolol is a non-selective beta-blocker that reduces the workload on the heart and slows down the heart rate. Bendroflumethiazide is a thiazide diuretic that promotes the excretion of sodium and water through the urine, thereby reducing blood volume and lowering blood pressure.

The combination of these drugs works to lower blood pressure through different mechanisms, resulting in a more significant decrease in blood pressure than either medication alone. nadolol is a competitive antagonist of beta-adrenergic receptors, meaning it binds to these receptors and blocks the effects of the neurotransmitter’s epinephrine and norepinephrine.

This results in decreased heart rate decreased force of contraction of the heart muscle, and reduced blood pressure. Bendroflumethiazide acts by inhibiting the sodium-chloride symporter in the DCT of the nephron in the kidney, leading to increased excretion of sodium, chloride, and water in the urine. This reduces blood volume and, subsequently, blood pressure.

Pharmacodynamics

nadolol is a beta-adrenergic receptor blocker that works by blocking the action of epinephrine and norepinephrine on beta receptors, leading to a decrease in heart rate and cardiac output. Bendroflumethiazide is a thiazide diuretic that works by inhibiting the reabsorption of chloride and sodium in the distal renal tubules, resulting in increased excretion of sodium, chloride, and water.

When used together, nadolol and Bendroflumethiazide work to lower blood pressure through two different mechanisms. nadolol slows down the heart rate and reduces cardiac output, which reduces the workload on the heart and lowers blood pressure. Bendroflumethiazide increases the excretion of sodium and water, which decreases the volume of fluid in the blood vessels and lowers blood pressure. The combination of nadolol and Bendroflumethiazide is used to treat hypertension.

pharmacokinetics

nadolol is a non-selective beta-adrenergic receptor blocker while bendroflumethiazide is a thiazide diuretic. nadolol is well-absorbed after oral administration and reaches peak plasma concentrations within 2 to 4 hours. It has an elimination half-life of 20 to 24 hours and is primarily eliminated through hepatic metabolism.

Bendroflumethiazide is also well-absorbed after oral administration and reaches peak plasma concentrations within 1 to 2 hours. It has an elimination half-life of 3 to 4 hours and is primarily eliminated through renal excretion. The combination of nadolol and bendroflumethiazide results in a decreased antihypertensive effect compared to either drug alone, but this effect can be minimized by adjusting the doses of the individual drugs.

Adminstartion

Administration

nadolol and bendroflumethiazide are typically administered orally in the form of tablets. The frequency and dosage of administration will depend on the specific formulation and the patient’s individual needs.

It is important to follow the instructions provided by the healthcare provider and to take the medication at the same time each day for optimal effectiveness. nadolol and bendroflumethiazide should be taken with food or immediately after a meal to minimize gastrointestinal side effects.

Patient Information Leaflet

Patient information leaflet

Generic Name: nadolol and bendroflumethiazide 

Pronounced: (NAD-oh-lol -and- BEN-droe-floo-meth-EYE-a-zide)

Why do we use nadolol and bendroflumethiazide?

nadolol and Bendroflumethiazide are combination medications used to treat hypertension (high blood pressure). The medication works by relaxing blood vessels, which helps to lower blood pressure.

nadolol is a beta-blocker that acts by blocking natural substances in the body, such as epinephrine, on the heart and blood vessels. This resulted in a slower heart rate and decreased blood pressure. Bendroflumethiazide is a thiazide diuretic that works by reducing the amount of salt and water in the body, which also helps to lower blood pressure.